Results 131 to 140 of about 5,378 (170)
Some of the next articles are maybe not open access.
Human Placental Transfer of an Antifibrinolytic Agent (AMCA)
Acta Obstetricia et Gynecologica Scandinavica, 1970Abstract. A fibrinolytic inhibitor AMCA (trans pâaminomethyl cyclohexane carboxylic acid) was given i.v. in a dose of 0.01 g/kg bodyweight to 12 mothers about to be delivered by Caesarean section. Immediately after delivery the concentration of AMCA was determined in the maternal blood and in cord blood.
S, Kullander, I M, Nilsson
openaire +2 more sources
The Use of Antifibrinolytic Agents in Spine Surgery
The Journal of Bone and Joint Surgery-American Volume, 2008Antifibrinolytic agents have been shown to decrease the blood loss associated with major orthopaedic surgical procedures. Spine surgery, particularly procedures performed for deformity correction and procedures involving long arthrodesis constructs, can be associated with a large amount of blood loss requiring blood transfusions.
J Brian, Gill +3 more
openaire +2 more sources
A Direct Antifibrinolytic Agent in Major Orthopedic Surgery
Orthopedics, 2004abstract Aprotinin is a potent pharmacological agent that reduces bleeding. In current surgical practices, the rate of blood transfusions has decreased with the use of aprotinin. Recently, studies using aprotinin have been conducted in orthopedic surgery.
openaire +2 more sources
Studies on an antifibrinolytic agent trans-AMCHA
Acta Medicinae Okayama, 1968Lysis of fibrin was first recognized by MORGAGNI in 1769, observing a liquid blood in a patient of acute death, and the phenomenon was named as fibrinolysis by DASTRE in 1893. In 1937, MACFARLANE recognized in a patient after cholecystectomy that the blood clot was lysed completely in the following morning.
Sunada, Terutake +5 more
openaire +2 more sources
Antifibrinolytic Agents in Traumatic Hemorrhage
Annals of Epidemiology, 2006openaire +2 more sources